Second-generation aldosterone synthase inhibitors significantly reduced systolic blood pressure but increased hyperkalemia, hyponatremia, and hypotension versus placebo.
Do second-generation aldosterone synthase inhibitors reduce systolic blood pressure in patients with hypertension compared to placebo?
Second-generation ASIs effectively reduce systolic blood pressure in hypertension but are associated with increased risks of hyperkalemia, hyponatremia, and hypotension.
Absolute Event Rate: 0% vs 0%
Second-generation ASIs had a high likelihood of a clinically significant reduction in SBP compared with placebo. However, hyperkalemia, hyponatremia, and hypotension were more frequent with ASIs.
Queiroga et al. (Sun,) reported a other. Second-generation aldosterone synthase inhibitors significantly reduced systolic blood pressure but increased hyperkalemia, hyponatremia, and hypotension versus placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: